CHEN Guijin,LIN Wei,ZHANG Chaohui, et al. VOSviewer-based visualization analysis on research hot topics and frontiers in immunotherapy for gastric cancer[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2023, 53(11): 923-929.
摘要目的：通过文献计量和知识图谱可视化分析胃癌免疫治疗的研究现状、热点和前沿，为该领域研究提供参考。方法：从Web of Science核心合集中的科学引文索引扩展版数据库中检索2018年1月1日至2023年7月6日发表的有关胃癌免疫治疗的文献，筛选符合标准的文献，使用Web of Science、InCite、Excel、VOSviewer等工具对文献进行计量分析和可视化分析。结果：最终选取878 篇文献，年发文量呈总体上升趋势；发文量排前三的国家依次是中国、日本和美国；发文量排前三的机构依次是日本国立癌症中心、复旦大学和首尔大学；核心作者合作网络分析显示，日本和韩国的研究人员在该领域的合作较密切，形成了4个合作关系紧密、成员较多的合作团体，中国研究人员与国外的合作较少，合作网络较松散；关键词词频分析和聚类分析显示免疫检查点阻断是胃癌主要的免疫治疗方式，免疫检查点抑制剂，尤其是程序性死亡受体1抑制剂，及其与化疗/靶向药物的联合治疗，免疫治疗疗效及预后的预测与相关生物标志物是该领域的热点和前沿。结论：近六年来胃癌免疫治疗的研究快速发展，我国是该领域的主要研究国家，应加强对胃癌免疫治疗的疗效及预后的预测、基于免疫治疗的联合治疗等热点问题的探索，同时加强国内外合作，提高研究质量，促进该领域的发展。
Abstract：Objective: To analyze the researches on the immunotherapy for gastric cancer and explore the research hot spots and frontiers. Methods: The literature on immunotherapy for gastric cancer published between January 1, 2018 and July 6, 2023 from the science citation index expanded database was searched. Web of Science,InCite, Excel and VOSviewer were used to analyze the countries, institutions, authors and keywords, and knowledge mapping was drawn. Results: A total of 878 articles were included, and the annual publication number showed a general upward trend, with China, Japan and the United States ranking the top three in the number of articles published. The top three institutions in order were the National Cancer Center - Japan, Fudan University,and Seoul National University. The co-occurrence analysis of the core authors showed that Japanese and South Korean researchers had close collaborative relationship in this field, while Chinese researchers had loose collaborative relationship. Frequency analysis and cluster analysis of keywords showed that immune checkpoint blocking was the main immunotherapy for gastric cancer. The hot topics and frontiers were biomarkers or models predicting the prognosis and immunotherapy response in gastric cancer, immune checkpoint inhibitors, especially PD-1 inhibitors, and their combination with chemotherapy/targeted drugs. Conclusion: The immunotherapy for gastric cancer has developed rapidly in the past six years. China is the main research country of the field, and we should continue to focus on the hot topics such as the combined therapy with immunotherapy, the prediction of the efficacy and prognosis of immunotherapy. Meanwhile, China could encourage and strengthen domestic andforeign cooperation to improve the research quality and promote the development in this field.
